These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
289 related articles for article (PubMed ID: 17631180)
41. The causes and prognostic significance of low hemoglobin levels in tumor patients. Manegold C Strahlenther Onkol; 1998 Dec; 174 Suppl 4():17-9. PubMed ID: 9879342 [TBL] [Abstract][Full Text] [Related]
42. Update on erythropoiesis-stimulating agents and clinical trials in oncology. Aapro M; Spivak JL Oncologist; 2009; 14 Suppl 1():6-15. PubMed ID: 19762512 [TBL] [Abstract][Full Text] [Related]
43. Alternatives to blood product transfusion in the critically ill: erythropoietin. Stubbs JR Crit Care Med; 2006 May; 34(5 Suppl):S160-9. PubMed ID: 16617261 [TBL] [Abstract][Full Text] [Related]
44. [Efficacy of weekly epoetin Beta in the treatment of chemotherapy-induced anemia in solid tumors]. Oudard S; Quoix E; Jenabian A; Bergougnoux L; Chouahnia K; Ferrero JM; Misset JL; Spaëth D Therapie; 2009; 64(1):17-25. PubMed ID: 19463249 [TBL] [Abstract][Full Text] [Related]
45. Erythropoietin for oncology supportive care. McKinney M; Arcasoy MO Exp Cell Res; 2011 May; 317(9):1246-54. PubMed ID: 21396935 [TBL] [Abstract][Full Text] [Related]
46. Editorial: anemia management with erythropoiesis-stimulating agents: a risk-benefit update. Aapro MS Oncologist; 2008; 13 Suppl 3():1-3. PubMed ID: 18458117 [No Abstract] [Full Text] [Related]
47. Anemia in multiple myeloma. Ludwig H; Pohl G; Osterborg A Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188 [TBL] [Abstract][Full Text] [Related]
48. Controversies in the management of the anemia of prematurity using single-donor red blood cell transfusions and/or recombinant human erythropoietin. Strauss RG Transfus Med Rev; 2006 Jan; 20(1):34-44. PubMed ID: 16373186 [TBL] [Abstract][Full Text] [Related]
49. Optimizing anemia management in hospitalized patients with end-stage renal disease. Heung M; Mueller BA; Segal JH Ann Pharmacother; 2009 Feb; 43(2):276-82. PubMed ID: 19141655 [TBL] [Abstract][Full Text] [Related]
50. Benefits of early intervention with erythropoiesis- stimulating proteins in chemotherapy-induced anemia. Lyman GH Oncology (Williston Park); 2006 Jul; 20(8 Suppl 6):16-20. PubMed ID: 16925106 [TBL] [Abstract][Full Text] [Related]
51. Anemia and infections in multiple myeloma: supportive therapy. Cáceres W; Santiago K; Paulo L; Román J Bol Asoc Med P R; 2009; 101(2):50-2. PubMed ID: 19954102 [TBL] [Abstract][Full Text] [Related]
52. The role of the pharmacist in optimizing the use of erythropoietin stimulating agents. Gebara SN; Moubayed H J Oncol Pharm Pract; 2010 Mar; 16(1):33-7. PubMed ID: 19401308 [TBL] [Abstract][Full Text] [Related]
53. Treating anemia in patients with cancer. Tecnologica; 2001 Oct; ():1, 3-8. PubMed ID: 11776275 [No Abstract] [Full Text] [Related]
55. Erythropoietic agents in the management of cancer patients. Part 1: Anemia, quality of life, and possible effects on survival. Smith RE J Support Oncol; 2003; 1(4):249-56, 258-9; discussion 257-8. PubMed ID: 15334867 [TBL] [Abstract][Full Text] [Related]
56. Mechanisms of anaemia in patients with malignancy: implications for the clinical use of recombinant human erythropoietin. Cazzola M Med Oncol; 2000 Nov; 17 Suppl 1():S11-6. PubMed ID: 11188780 [TBL] [Abstract][Full Text] [Related]
57. Erythropoiesis-stimulating agents versus RBC transfusion in MDS: comparison of long-term outcomes. Mundle SD Future Oncol; 2007 Aug; 3(4):397-403. PubMed ID: 17661714 [TBL] [Abstract][Full Text] [Related]
60. Prediction of response and other improvements on the limitations of recombinant human erythropoietin therapy in anemic cancer patients. Beguin Y Haematologica; 2002 Nov; 87(11):1209-21. PubMed ID: 12414352 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]